Dr. Songqing Ye: Analysis of 2024 ASCO Breast Cancer ADC Research Progress

Dr. Songqing Ye: Analysis of 2024 ASCO Breast Cancer ADC Research Progress

At the 2024 ASCO Conference, the progress in breast cancer ADC (antibody-drug conjugate) research was remarkable. T-DXd demonstrated excellent efficacy in HER2-positive breast cancer, significantly extending patient survival and reinforcing the concept of using the best drugs first. In HR-positive and triple-negative breast cancer, Dato-DXd showed good safety and efficacy, laying the foundation for future combination therapy regimens. Additionally, domestic ADC drugs like ARX788 and SKB264 provided new treatment options for breast cancer patients. In this article, Dr. Songqing Ye from Fujian Provincial Hospital provides an in-depth analysis of the latest research findings on ADC drugs in HER2-positive, HR-positive, and triple-negative breast cancer presented at the 2024 ASCO Conference.
Dr. Litao Zhang Interprets Wuhan Asia General Hospital’s Innovative Anticoagulation Research

Dr. Litao Zhang Interprets Wuhan Asia General Hospital’s Innovative Anticoagulation Research

From June 22 to June 26, 2024, the 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) conference was successfully held in Bangkok, Thailand. At this prestigious event, the research achievements of Dr. Litao Zhang's team from Wuhan Asia General Hospital shone brightly. Several studies on anticoagulation management were selected, showcasing their significant contributions and expertise in the field of thrombosis and hemostasis. "Oncology Frontier - Hematology Frontier" invited Dr. Litao Zhang to comprehensively interpret the research content of his team. Here, we have compiled and invite you to join us in sharing this academic breeze.
BOC/BOA 2024 | Dr. Ye Guo Shares Advances in Head and Neck Tumor Research and Benefits of Personalized Treatment

BOC/BOA 2024 | Dr. Ye Guo Shares Advances in Head and Neck Tumor Research and Benefits of Personalized Treatment

Head and neck tumors are common malignant tumors among Chinese residents, significantly impacting organ function, quality of life, and prognosis due to disease progression and treatment effects. The "2024 Annual Progress in Clinical Oncology Conference (BOC) and Best of ASCO 2024 China" was recently held in Guangzhou, showcasing the progress of clinical oncology research in China and sharing cutting-edge information from the ASCO conference. On this occasion, "Oncology Frontier" invited Dr. Ye Guo from Shanghai East Hospital , Tongji University to share key research insights related to head and neck tumors.
The visit of Dr. Tao Cheng, President of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

The visit of Dr. Tao Cheng, President of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

From July 11 to 12, Dr. Tao Cheng, President of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS), and his delegation visited Thailand. They met with representatives from the Ministry of Public Health of Thailand, the Embassy of The People's Republic of China in the Kingdom of Thailand , Chulalongkorn University Medical School, and Medpark Hospital, and signed a strategic agreement with Faculty of Medicine, Chulalongkorn University.
BOC/BOA 2024 | Dr. Zhitao Ying: Annual Advances in Chinese Clinical Oncology 2023 ——Lymphoma)

BOC/BOA 2024 | Dr. Zhitao Ying: Annual Advances in Chinese Clinical Oncology 2023 ——Lymphoma)

Since 2015, the Chinese Society of Clinical Oncology (CSCO) has been dedicated to presenting annual reports on the progress of clinical oncology in China, under the theme "International Standards, Chinese Characteristics, Learning and Innovation." At the recent "2024 Annual Progress in Chinese Clinical Oncology Conference (BOC) and Best of ASCO 2024 China," the latest "Annual Advances in Chinese Clinical Oncology 2023" report was officially released. At this conference, Dr. Zhitao Ying from the Cancer Institute & Hospital Chinese Academy of Medical Sciences presented a detailed report on the advancements in lymphoma research in China for 2023.
Dr. Huiqiang Huang: Advances in Clinical Immunotherapy for Lymphoma, Highlighting PD-1/PD-L1 Antibody Combination Therapies

Dr. Huiqiang Huang: Advances in Clinical Immunotherapy for Lymphoma, Highlighting PD-1/PD-L1 Antibody Combination Therapies

In the realm of immunotherapy for lymphoma, PD-1/PD-L1 antibody combination therapies have emerged as a prominent area of research due to their precise modulation of the immune response. These therapies hold immense potential for enhancing efficacy and ensuring safety, providing lymphoma patients with more treatment options and the possibility of improved quality of life and prognosis. At the recent "2024 Nanjing Lymphoma Forum," Dr.  Huiqiang Huang from the Sun Yat-sen University Cancer Center delivered an outstanding presentation titled "Advances in Immunotherapy for Lymphoma: Clinical Exploration of PD-1/PD-L1 Antibody Combination Therapies." Following the forum, "Oncology Frontier - Hematology Frontier" invited Dr.  Huang for an interview to share further insights on this topic.
Dr. Zhangyin Ming: TGF-β1 Released by Platelets Promotes Tumor Cell Autophagy, Mediates Epithelial-Mesenchymal Transition, and Tumor Metastasis

Dr. Zhangyin Ming: TGF-β1 Released by Platelets Promotes Tumor Cell Autophagy, Mediates Epithelial-Mesenchymal Transition, and Tumor Metastasis

From June 22 to June 26, 2024, the 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) conference was successfully held in Bangkok, Thailand. At this year's conference, a study by Dr. Zhangyin Ming's team from the School of Basic Medicine, Tongji Hospital of Huazhong University of Science and Technology, explored "The Role of Platelets in Epithelial-Mesenchymal Transition (EMT) and Tumor Metastasis of Cancer Cells in Situ." "Oncology Frontier - Hematology Frontier" invited Dr. Zhangyin Ming to provide an in-depth analysis of the research content. Here is a detailed summary for our readers.
EHA Expert Interview | Dr. Sizhou Feng: Insights from Resistant Bacterial Colonization in Hematology Patients for Empirical Therapy

EHA Expert Interview | Dr. Sizhou Feng: Insights from Resistant Bacterial Colonization in Hematology Patients for Empirical Therapy

Patients undergoing hematopoietic stem cell transplantation and high-dose chemotherapy for hematological diseases have impaired immune function, making them highly susceptible to febrile neutropenia and colonization or infection with resistant bacteria. Prompt and accurate initiation of empirical therapy is crucial to improve patient outcomes. At the 2024 European Hematology Association (EHA) Annual Meeting, Dr. Sizhou Feng's team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, reported a study showing a high proportion of bloodstream infections caused by carbapenem-resistant Acinetobacter spp. (CRA) in hematology patients, with homology between bloodstream isolates and colonizing bacteria. This indicates the need to strengthen hospital infection control to reduce resistant bacterial colonization and to promptly initiate appropriate empirical antimicrobial therapy for suspected infections in patients colonized with resistant bacteria. "Oncology Frontier - Hematology Frontier" invited Dr. Sizhou Feng to introduce and interpret this research at the EHA meeting.
Epigenetic Changes and Chromatin Architecture in Lipid Metabolic Reprogramming During Trastuzumab Adaptation in HER2-Positive Breast Cancer

Epigenetic Changes and Chromatin Architecture in Lipid Metabolic Reprogramming During Trastuzumab Adaptation in HER2-Positive Breast Cancer

In a significant advancement in breast cancer research, Dr. Yongmei Yin and her team from The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital published the article "Unveiling Alterations of Epigenetic Modifications and Chromatin Architecture Leading to Lipid Metabolic Reprogramming during the Evolutionary Trastuzumab Adaptation of HER2-Positive Breast Cancer" in Advanced Science on May, 2024. This pivotal study investigates the epigenetic and chromatin structural changes that lead to metabolic reprogramming during the development of trastuzumab resistance in HER2-positive breast cancer. HER2-positive breast cancer is characterized by the overexpression of the HER2 protein, which promotes the growth of cancer cells. Trastuzumab, a monoclonal antibody, targets the HER2 protein but is met with resistance in many patients over time. This study addresses the urgent need to understand the underlying mechanisms of trastuzumab resistance to improve treatment strategies.
Dr. Zefei Jiang：Neoadjuvant-Adjuvant Pertuzumab in HER2-Positive Early Breast Cancer: Final Analysis of the Randomized Phase III PEONY Trial

Dr. Zefei Jiang：Neoadjuvant-Adjuvant Pertuzumab in HER2-Positive Early Breast Cancer: Final Analysis of the Randomized Phase III PEONY Trial

Dr. Zefei Jiang from The Fifth Medical Center of  Chinese PLA General Hospital, along with his colleagues, published the groundbreaking article titled "Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial" in Nature Communications  on March 9, 2024. This pivotal research examines the long-term efficacy and safety of incorporating pertuzumab, a monoclonal antibody, into the treatment regimen for HER2-positive early and locally advanced breast cancer. HER2-positive breast cancer is characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells. Pertuzumab targets the HER2 receptor, working synergistically with trastuzumab, another HER2-targeted therapy, to provide a more effective treatment approach.